[Allergen specific immunotherapy: new approaches].
Specific immunotherapy (SIT) is the only disease-modifying and causal treatment of IgE mediated allergic diseases. Soon this treatment will turn 100 years old. Subcutaneous immunotherapy is still considered to be the gold standard of SIT. With the intention to improve efficacy, safety and desirability for patients, new strategies such as epicutaneous immunotherapy, i.e. administration of allergens using a skin patch, are under investigation in clinical trials at the Zurich University Hospital.
Clinical Trials Center, Zentrum für Klinische Forschung, Universitätsspital und Universität Zürich, Zürich. fabian.tay@usz.ch
F
F
Tay
T M
TM
Kündig
G
G
Senti
D000279:Administration, Cutaneous; D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology*; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000379:methods*; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D007279:Injections, Subcutaneous; D008198:Lymph Nodes / Q000187:drug effects; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology* / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology* / Q000628:therapy*
D000485:Allergens; D000939:Epitopes